AIM Stock - Aerosonic Corp.

AIM Stock Chart

AIM Profile

AIM ImmunoTech Inc. is a pioneering immuno-pharma company based in Ocala, Florida, dedicated to advancing therapeutics for a wide spectrum of cancers, viral diseases, and immune-deficiency disorders. The company focuses on developing Ampligen, a unique macromolecular RNA-based drug designed initially for treating chronic fatigue syndrome (CFS). Ampligen's applications extend to potential treatments for renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate, and pancreatic cancers, as well as myalgic encephalomyelitis (ME), Hepatitis B, HIV, COVID-19, and related post-COVID conditions.

In addition to Ampligen, AIM ImmunoTech offers Alferon N Injection, an injectable formulation of natural alpha interferon utilized for treating genital warts, a sexually transmitted disease. The company collaborates extensively through agreements with UMN Pharma Inc., the Japanese National Institute of Infectious Diseases, Shionogi & Co., Ltd., Polysciences Inc., and the University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. These partnerships underscore AIM ImmunoTech's commitment to advancing medical research and expanding therapeutic options across global healthcare markets.

Founded in 1966 and previously known as Hemispherx Biopharma, Inc., AIM ImmunoTech underwent a name change in August 2019 to reflect its focused mission in immunotherapy and immune modulation. With a legacy of innovation spanning decades, AIM ImmunoTech continues to drive forward with cutting-edge research and development aimed at addressing critical unmet medical needs through its advanced biopharmaceutical solutions.

AIM Revenue Chart

AIM Earnings

Analyst Ratings